Indian stocks: Visit www.stage2stocks.com →

DiaMedica Therapeutics Inc.

Stage 2 · Advancing · week 2

As of Oct 22, 2026, DiaMedica Therapeutics is in Stage 2, the uptrend phase, now in week 2 (since Oct 13, 2026). It closed at $8.63, 8.1% below its 52-week high and above its 200-day average, which is falling.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. More about the company

$8.63
-0.69% today
$465M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is DMAC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 37w
S2 25w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 2w → S3 11w → S4 5w → S1 7w → S2 2w → S1 6w → S4 1w → S3 2w → S4 2w → S3 2w → S2 3w → S3 4w → S2 37w → S3 5w → S4 8w → S1 1w → S4 1w → S1 7w → S2 25w → S3 9w → S4 10w → S1 11w → S4 2w → S1 1w → S2 1w current
Total tracked: 165 weeks across 25 stage runs.

DMAC among Biotechnology116th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…116DMACStage 2 · wk 277+14.2%
vs 52W High
-8.1%
$5.33 lo$9.39 hi
8.1% below 52W high, pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 2
1w13w26w
Week 2, fresh breakout
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
21.8%
200 DMA: $7.09 · sloping down
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.47x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
Short-term trend rising strongly
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+14.2%
3M
+28.1%
6M
+38.7%
YTD
+8.8%
1Y
+30.4%
Scan Membership
Breakout Watch
Latest: 2024-07-10
8 appearances in last 60 days. First seen: 2019-08-20.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 2 · Vol 0.47x
2026-10-21S2
Wk 2 · Vol 0.74x
2026-10-20S2
Wk 2 · Vol 0.90x
2026-10-19S2
Wk 1 · Vol 1.01x
2026-10-16S2
Wk 1 · Vol 1.43x
2026-10-15S2
Wk 1 · Vol 1.70x
2026-10-14S2
Wk 1 · Vol 1.62x
2026-10-13S21→2
Wk 1 · Vol 1.46x
2026-10-12S1
Wk 1 · Vol 1.07x
2026-10-09S1
Wk 1 · Vol 0.97x
2026-10-08S1
Wk 1 · Vol 1.36x
2026-10-07S1
Wk 1 · Vol 1.25x
Moving averages & range
50 DMA
$7.31
200 DMA
$7.09
52W High
$9.39
52W Low
$5.33
5D Low
$7.57
Resistance levels (recent highs)
20d High
$8.69
60d High
$8.69
120d High
$8.69
250d High
$9.39
Next resistance
+0.7%
to 20d High
ROE
-114.6%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 12.1

DiaMedica Therapeutics: quick answers

What stage is DiaMedica Therapeutics in?

As of Oct 22, 2026, DiaMedica Therapeutics (DMAC) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 13, 2026 and is in week 2. What the four stages mean

Is DiaMedica Therapeutics in an uptrend?

Yes. DiaMedica Therapeutics is in a Stage 2 uptrend. It trades 21.8% above its 200-day average, which is falling.

How far is DiaMedica Therapeutics from its 52-week high?

DiaMedica Therapeutics closed at $8.63 on Oct 22, 2026, 8.1% below its 52-week high of $9.39. Its 52-week low is $5.33.

How has DiaMedica Therapeutics performed over the past year?

As of Oct 22, 2026, DiaMedica Therapeutics is up 30.4% over the past year and up 8.8% so far in 2026.

Which sector and industry is DiaMedica Therapeutics in?

DiaMedica Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.